<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955770</url>
  </required_header>
  <id_info>
    <org_study_id>01-8/464-15</org_study_id>
    <nct_id>NCT03955770</nct_id>
  </id_info>
  <brief_title>Effects of HFOT on Exercise Performance in Patients With COPD. A Randomized, Controlled Trial.</brief_title>
  <official_title>Effects of High Flow Oxygen Therapy on Exercise Performance in Patients With Chronic Obstructive Pulmonary Disease. A Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, cross-over trial evaluating the efficacy of nasal high-flow oxygen
      therapy (HFOT) vs. low-flow oxygen therapy (LFOT) on cycling endurance in patients with
      chronic obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, cross-over trial evaluating the efficacy of nasal HFOT vs. LFOT on
      cycling endurance in patients with COPD. Each patient will perform two constant load cycling
      exercise tests to exhaustion using HFOT and LFOT on two consecutive days, respectively,
      according to randomization. The load of the cycle ergometer will be set at 75% of the
      individually estimated maximum work rate (Wmax). During exercise tests, LFOT will be provided
      by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator. HFOT will
      be applied by a dedicated large bore nasal cannula at a flow rate 60 L/min, FiO2 45%,
      temperature 32 °C, using a HFOT device.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Actual">August 2, 2019</completion_date>
  <primary_completion_date type="Actual">August 2, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise endurance time in seconds</measure>
    <time_frame>HFOT on day 1 vs. LFOT on day 2 or vice versa, according to randomization</time_frame>
    <description>Difference in the exercise endurance time between HFOT vs. LFOT during a constant load exercise test at 75% of the maximal work capacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea sensation</measure>
    <time_frame>HFOT on day 1 vs. LFOT on day 2 or vice versa, according to randomization</time_frame>
    <description>Difference in the exercise induced dyspnea sensation between HFOT vs LFOT assessed by the BORG CR10 scale ranging from 0 &quot;no dyspnea at all&quot; to 10 &quot;Maximum of dyspnea&quot; assessed at the end of exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective leg fatigue sensation</measure>
    <time_frame>HFOT on day 1 vs. LFOT on day 2 or vice versa, according to randomization</time_frame>
    <description>Difference in the exercise induced subjective leg fatigue sensation between HFOT vs LFOT assessed by the BORG CR10 scale ranging from 0 &quot;no leg fatigue at all&quot; to 10 &quot;Maximum of leg fatigue&quot; assessed at the end of exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood gases</measure>
    <time_frame>HFOT on day 1 vs. LFOT on day 2 or vice versa, according to randomization</time_frame>
    <description>Difference of parameters in the arterial blood gases, in particular pH, SaO2, PaO2 and PaCO2 between HFOT vs. LFOT at the end of exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate in bpm</measure>
    <time_frame>HFOT on day 1 vs. LFOT on day 2 or vice versa, according to randomization</time_frame>
    <description>Difference in the maximal heart rate assessed by ECG between HFOT vs. LFOT at the end of exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood pressure in mmHg</measure>
    <time_frame>HFOT on day 1 vs. LFOT on day 2 or vice versa, according to randomization</time_frame>
    <description>Difference in the maximal blood pressure between HFOT vs. LFOT at the end of exercise.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>HFOT first then LFOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LFOT first then HFOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>High-flow oxygen therapy (HFOT)</intervention_name>
    <description>HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher&amp;Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher&amp;Paykel, New Zealand).</description>
    <arm_group_label>HFOT first then LFOT</arm_group_label>
    <arm_group_label>LFOT first then HFOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Low-flow oxygen therapy (LFOT)</intervention_name>
    <description>LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).</description>
    <arm_group_label>HFOT first then LFOT</arm_group_label>
    <arm_group_label>LFOT first then HFOT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Men and women, 35 to 75 years of age, with moderate to severe COPD, (FEV1/FVC &lt;0.7, FEV1
        40-80% predicted, resting SpO2 ≥92%, PaCO2 &lt;6 kPa at 760 m) who live &lt;800 m will be
        invited.

        Exclusion criteria:

        COPD exacerbation, very severe COPD with hypoxemia (FEV1/FVC &lt;0.7, FEV1 &lt;40% predicted,
        oxygen saturation on room air &lt;92%), current heavy smoking (&gt;20 cigarettes per day),
        comorbidities such as uncontrolled cardiovascular disease, internal, neurologic,
        rheumatologic or psychiatric disease that interfere with protocol compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Furian, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konrad E Bloch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Talant M Sooronbaev, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Center of Cardiology and Internal Medicine, Bishkek</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center of Cardiology and Internal Medicine</name>
      <address>
        <city>Bishkek</city>
        <country>Kyrgyzstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kyrgyzstan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exercise endurance</keyword>
  <keyword>High-flow oxygen therapy</keyword>
  <keyword>Low-flow oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

